Opinion

Video

Determining Which DTC Patients May Benefit from Systemic Therapy

Hyunseok Kang, MD, discusses the importance of balancing toxicities and other factors when initiating first-line treatments for patients with refractory differentiated thyroid cancer (DTC), while emphasizing the need to set clear goals and communicate potential adverse reactions before allowing patients to make informed decisions.

Related Videos
Terence W. Friedlander, MD
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Terence W. Friedlander, MD
5 KOLs are featured in this series.
5 KOLs are featured in this series.